MX361923B - Compuestos macrociclicos totalmente sinteticos limitados de modo conformacional. - Google Patents
Compuestos macrociclicos totalmente sinteticos limitados de modo conformacional.Info
- Publication number
- MX361923B MX361923B MX2014011078A MX2014011078A MX361923B MX 361923 B MX361923 B MX 361923B MX 2014011078 A MX2014011078 A MX 2014011078A MX 2014011078 A MX2014011078 A MX 2014011078A MX 361923 B MX361923 B MX 361923B
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- variety
- ring system
- activity
- macrocycles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
Abstract
El sistema de anillo macrocíclico de la formula (I) definido espacialmente y restringido de modo conformacional, se encuentra constituido por tres partes moleculares distintas: Plantilla A, Modulador B de conformación y Puente C. Los macrociclos descritos por este sistema de anillo I se fabrican fácilmente por síntesis en paralelo o química combinatorial en solución o en fase sólida. Se diseñan para interactuar con una variedad de clases de objetivos biológicos específicos, ejemplos son su actividad agonista o antagonista sobre los receptores acoplados a la proteína G (GPCR), la actividad inhibidora sobre las enzimas o su actividad antimicrobiana. En particular, estos macrociclos muestran una actividad inhibidora en la enzima que convierte endotelina del subtipo 1 (ECE-1) y/o la cisteína proteasa de catepsina S (CatS), y/o actúan como antagonistas del receptor de oxitocina (OT), el receptor de hormona que libera tirotropina (TRH) y/o receptor B4 de leucotrieno (LTB4), y/o como agonistas del receptor de bombesina 3 (BB3), y/o muestran actividad antimicrobiana contra al menos una cepa bacteriana. De este modo, también muestran gran potencial como medicamentos para una variedad de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001830 | 2012-03-17 | ||
PCT/EP2013/055368 WO2013139697A1 (en) | 2012-03-17 | 2013-03-15 | Conformationally constrained, fully synthetic macrocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014011078A MX2014011078A (es) | 2014-11-21 |
MX361923B true MX361923B (es) | 2018-12-19 |
Family
ID=47882188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014011078A MX361923B (es) | 2012-03-17 | 2013-03-15 | Compuestos macrociclicos totalmente sinteticos limitados de modo conformacional. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10017481B2 (es) |
EP (1) | EP2836485B1 (es) |
JP (1) | JP6111276B2 (es) |
CN (1) | CN104284891B (es) |
AU (1) | AU2013234499B2 (es) |
CA (1) | CA2867494C (es) |
DK (1) | DK2836485T3 (es) |
HK (1) | HK1206032A1 (es) |
IL (1) | IL234595A (es) |
MX (1) | MX361923B (es) |
NZ (1) | NZ630901A (es) |
SG (1) | SG11201405628YA (es) |
WO (1) | WO2013139697A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104090A1 (en) | 2007-02-28 | 2008-09-04 | Polyphor Ag | Template-fixed peptidomimetics |
WO2016061097A1 (en) * | 2014-10-13 | 2016-04-21 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
GB201509006D0 (en) * | 2015-05-26 | 2015-07-08 | Redx Pharma Plc | Antibacterial compounds |
WO2017063757A1 (en) | 2015-10-12 | 2017-04-20 | Polyphor Ag | Conformationally constrained macrocyclic compounds |
WO2017063755A1 (en) | 2015-10-12 | 2017-04-20 | Polyphor Ag | Conformationally constrained macrocyclic compounds |
WO2017063754A1 (en) | 2015-10-12 | 2017-04-20 | Polyphor Ag | Conformationally constrained macrocyclic compounds as pin1 modulators |
GB201705686D0 (en) * | 2017-04-07 | 2017-05-24 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
CA3155885A1 (en) | 2019-11-25 | 2021-06-03 | Lewis D. Pennington | Substituted macrocyclic compounds and related methods of treatment |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
WO2023225661A1 (en) * | 2022-05-20 | 2023-11-23 | Bristol-Myers Squibb Company | Macrocyclic immunomodulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2399247A1 (fr) * | 1977-08-04 | 1979-03-02 | Rhone Poulenc Ind | Antibiotique 35665 rp, sa preparation et les compositions qui les contiennent |
JPS6016236B2 (ja) * | 1977-11-18 | 1985-04-24 | 武田薬品工業株式会社 | 抗生物質c―15003 p―3の製造法 |
CN102584940B (zh) * | 2005-01-13 | 2014-12-31 | 卧龙岗大学 | 肽化合物 |
CL2008000629A1 (es) * | 2007-03-01 | 2008-08-29 | Chugai Pharmaceutical Co Ltd | Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer. |
US7732434B2 (en) * | 2007-04-20 | 2010-06-08 | Bristol-Myers Squibb Company | Macrocyclic acyl guanidines as beta-secretase inhibitors |
MX2011012155A (es) * | 2009-05-13 | 2012-02-28 | Enanta Pharm Inc | Compuestos macrociclicos como inhibidores del virus de hepatitis c. |
EP2462147B8 (en) * | 2009-08-05 | 2015-03-18 | Polyphor AG | Conformationally constrained, fully synthetic macrocyclic compounds |
-
2013
- 2013-03-15 DK DK13709234.2T patent/DK2836485T3/en active
- 2013-03-15 JP JP2014561464A patent/JP6111276B2/ja active Active
- 2013-03-15 EP EP13709234.2A patent/EP2836485B1/en active Active
- 2013-03-15 SG SG11201405628YA patent/SG11201405628YA/en unknown
- 2013-03-15 NZ NZ630901A patent/NZ630901A/en not_active IP Right Cessation
- 2013-03-15 WO PCT/EP2013/055368 patent/WO2013139697A1/en active Application Filing
- 2013-03-15 MX MX2014011078A patent/MX361923B/es active IP Right Grant
- 2013-03-15 AU AU2013234499A patent/AU2013234499B2/en active Active
- 2013-03-15 US US14/385,689 patent/US10017481B2/en active Active
- 2013-03-15 CN CN201380024808.7A patent/CN104284891B/zh active Active
- 2013-03-15 CA CA2867494A patent/CA2867494C/en active Active
-
2014
- 2014-09-11 IL IL234595A patent/IL234595A/en active IP Right Grant
-
2015
- 2015-07-14 HK HK15106718.1A patent/HK1206032A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1206032A1 (en) | 2015-12-31 |
EP2836485A1 (en) | 2015-02-18 |
EP2836485B1 (en) | 2018-01-10 |
WO2013139697A1 (en) | 2013-09-26 |
JP2015509970A (ja) | 2015-04-02 |
SG11201405628YA (en) | 2014-10-30 |
US10017481B2 (en) | 2018-07-10 |
DK2836485T3 (en) | 2018-04-23 |
AU2013234499A1 (en) | 2014-10-09 |
US20150051183A1 (en) | 2015-02-19 |
NZ630901A (en) | 2015-09-25 |
AU2013234499B2 (en) | 2017-07-27 |
CN104284891A (zh) | 2015-01-14 |
CA2867494A1 (en) | 2013-09-26 |
JP6111276B2 (ja) | 2017-04-05 |
CN104284891B (zh) | 2018-04-17 |
MX2014011078A (es) | 2014-11-21 |
IL234595A (en) | 2016-08-31 |
CA2867494C (en) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ630901A (en) | Conformationally constrained, fully synthetic macrocyclic compounds | |
UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
CL2007001885A1 (es) | Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis. | |
CA2797033C (en) | Highly active polypeptides and methods of making and using the same | |
BR112013030281A2 (pt) | espiro-[1,3]-oxazinas e espiro-[1,4]-oxazepinas como inibidores de bace1 e/ou bace2 | |
MX2010005905A (es) | Compuestos multi-objetivo activos en un receptor de ppar y cannabinoide. | |
WO2011014973A3 (en) | Conformationally constrained, fully synthetic macrocyclic compounds | |
GEP20135961B (en) | Fused ring compounds and usage thereof | |
WO2007115077A3 (en) | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators | |
MX2009006304A (es) | Nuevos compuestos de oxadiazol. | |
PE20141182A1 (es) | Derivados fusionados de aminodihidrotiazina | |
CL2013002667A1 (es) | Compuestos derivados de ciclohexil-pirimidinona; composicion farmaceutica y su uso como moduladores de receptores de glucocorticoides para el tratamiento de hipertension, obesidad, diabetes, depresion psicotica mayor, vih, enfermedad de alzheimer, enfermedad de parkinson y estres. | |
UY30783A1 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos | |
MX354458B (es) | Compuesto de guanidina. | |
BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
EA201070169A1 (ru) | 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы | |
AR065014A1 (es) | Derivado de heterocicliden-n-(aril)acetamida | |
EA201190168A1 (ru) | Терапевтические применения фракций мастиковой смолы | |
BR112014015630A8 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas, seus usos, e composição farmacêutica | |
MX358307B (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3. | |
WO2011094765A3 (en) | A targeting signal for integrating proteins, peptides and biological molecules into bacterial microcompartments | |
PH12014501540A1 (en) | 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives | |
AU2016334085B2 (en) | Modulating gamma - c -cytokine activity | |
BR112012017188A8 (pt) | composto agonista de mglu2, sua composição farmacêutica e seu uso | |
CO6470792A2 (es) | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |